<DOC>
	<DOCNO>NCT02394145</DOCNO>
	<brief_summary>Patients end stage renal disease ( ESRD ) hemodialysis ( HD ) exhibit high platelet reactivity clopidogrel normal renal function . We recently report platelet inhibition ticagrelor faster markedly great clopidogrel onset dose regimen patient ESRD HD . However , study conduct genetic influence high platelet reactivity patient ESRD HD .</brief_summary>
	<brief_title>Genotype Platelet Reactivity Patients Hemodialysis</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) strong risk factor cardiovascular morbidity mortality , confers increase risk stent thrombosis even dual antiplatelet therapy ( clopidogrel aspirin ) administer . Patients severe CKD end stage renal disease ( ESRD ) hemodialysis ( HD ) exhibit high platelet reactivity clopidogrel normal renal function . We recently report platelet inhibition ticagrelor markedly great clopidogrel patient ESRD HD . But exact mechanism high platelet reactivity ESRD patient fully evaluate . A possible postulation would genetic influence . To investigate issue , evaluate genetic polymorphism patient normal kidney function ESRD HD accord different dos clopidogrel ticagrelor . Genetic test assess polymorphism ABCB1 , PON1 , CYP2C19 , CYP2C9 P2Y12 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>ESRD patient undergo regular ( ≥ 6 month ) maintenance HD Matching patient normal kidney function document coronary artery disease high risk ( Framingham heart risk score ≥ 20 % ) coronary artery disease know allergy aspirin , clopidogrel , ticagrelor concomitant use antithrombotic drug ( oral anticoagulant , dipyridamole ) thrombocytopenia ( platelet count &lt; 100,000/mm3 ) hematocrit &lt; 25 % uncontrolled hyperglycemia ( hemoglobin A1c &gt; 10 % ) liver disease ( bilirubin level &gt; 2 mg/dl ) symptomatic severe pulmonary disease active bleeding bleed diathesis gastrointestinal bleeding within last 6 month hemodynamic instability acute coronary cerebrovascular event within last 3 month pregnancy malignancy concomitant use cytochrome P450 inhibitor nonsteroidal antiinflammatory drug recent treatment ( &lt; 30 day ) glycoprotein IIb/IIIa antagonist</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>platelet</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>genetics</keyword>
</DOC>